How to Get Rezdiffra (Resmetirom) in Virginia

What Is Rezdiffra (Resmetirom) and Why Does It Matter for Virginia Patients?

Rezdiffra (resmetirom) became the first and only FDA-approved pharmacotherapy for MASH on March 14, 2024. Before that date, clinicians managing metabolic dysfunction-associated steatohepatitis had no approved drug to offer. The MAESTRO-NASH trial, published in the New England Journal of Medicine in 2024, enrolled 966 patients on resmetirom 100 mg and showed that 25.9% achieved MASH resolution without worsening fibrosis at 52 weeks, compared with 9.7% on placebo (P<0.001) [1].

Virginia has roughly 8.7 million residents, and national prevalence data from the CDC suggest that nonalcoholic fatty liver disease affects approximately 25% of U.S. Adults [2]. That translates to a large pool of Virginians who may qualify for resmetirom.

How Resmetirom Works

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. THR-beta is expressed primarily in the liver and regulates lipid metabolism, mitochondrial function, and hepatic fat clearance [3]. By activating THR-beta selectively, resmetirom reduces hepatic triglyceride accumulation without the cardiac or bone side effects associated with non-selective thyroid hormone activity [1].

Approved Dose and Formulation

The FDA label specifies two weight-based doses: 80 mg once daily for patients weighing <100 kg, and 100 mg once daily for patients weighing 100 kg or more [4]. Both doses come as oral tablets taken with or without food. No injectable formulation exists. Patients with severe hepatic impairment (Child-Pugh C) should not use this drug, per the prescribing information [4].

Who Qualifies Clinically

The approved population is adults with MASH confirmed by liver biopsy showing moderate-to-advanced fibrosis (Ishak stage 1-3 or METAVIR F2-F3). Clinicians typically use noninvasive tests such as FIB-4 score, MRE (magnetic resonance elastography), or FibroScan to estimate fibrosis before biopsy [5]. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance identifies FIB-4 <1.3 as low risk and FIB-4 >2.67 as high risk, guiding the decision to proceed to biopsy [5].

MAESTRO-NASH Trial: The Core Evidence Behind Virginia Prescriptions

Every prior authorization in Virginia will reference MAESTRO-NASH. Knowing the trial makes the PA process faster.

Trial Design and Primary Endpoints

MAESTRO-NASH (NCT03900429) was a randomized, double-blind, placebo-controlled trial enrolling 966 patients at 80 mg resmetirom, 966 at 100 mg, and 966 on placebo across 245 sites globally, published in NEJM in March 2024 [1]. The co-primary endpoints were MASH resolution without worsening fibrosis, and fibrosis improvement by at least one stage without worsening MASH.

Key Efficacy Numbers

At 52 weeks on 100 mg resmetirom [1]:

• MASH resolution: 25.9% vs. 9.7% placebo (P<0.001)
• Fibrosis improvement by one or more stages: 24.2% vs. 14.2% placebo (P<0.001)
• LDL-C reduction: approximately 16.3% from baseline
• Non-HDL cholesterol reduction: approximately 18.0% from baseline

The 80 mg arm also met both co-primary endpoints, with MASH resolution in 22.4% vs. 9.7% placebo (P<0.001) [1].

Safety Profile Relevant to Virginia Prescribers

The most common adverse events were gastrointestinal: nausea (26% at 100 mg vs. 11% placebo) and diarrhea (28% vs. 16% placebo) [1]. Serious hepatic events were not significantly higher than placebo. Because resmetirom activates THR-beta, thyroid function should be monitored; the FDA label lists drug interactions with statins, specifically simvastatin and rosuvastatin, where dose adjustments may be required [4]. Clinicians in Virginia who co-prescribe statins must review those interactions before writing the resmetirom Rx.

Virginia Telehealth Rules for Prescribing Resmetirom

Virginia permits telehealth prescribing of resmetirom. The state's telehealth framework was codified under Virginia Code § 54.1-3303 and updated guidance from the Virginia Department of Health Professions [6]. A valid patient-provider relationship can be established via synchronous audio-video visit, meaning no prior in-person visit is required for most non-controlled substances.

What a Telehealth Visit Must Include

For resmetirom specifically, a telehealth prescriber must:

1. Review prior liver imaging or biopsy records confirming MASH with fibrosis staging.
2. Confirm the patient's current medication list (statin interactions are common).
3. Order or review baseline labs: ALT, AST, total bilirubin, albumin, INR, HbA1c, TSH, fasting lipid panel, and a FIB-4 calculation from CBC with differential.
4. Document body weight to select the correct dose (80 mg or 100 mg).
5. Confirm absence of Child-Pugh C cirrhosis.

Prescriber Types Allowed in Virginia

Virginia law permits MDs and DOs to prescribe independently. Nurse practitioners and physician assistants may prescribe under a collaborative agreement with a supervising physician [6]. For a specialty drug like resmetirom, most telehealth platforms require NP and PA prescribers to have the collaborating physician review and co-sign orders related to MASH treatment, given the YMYL complexity of the indication.

Finding a Virginia Telehealth Provider

HealthRX connects Virginia patients with board-certified gastroenterologists and hepatologists for telehealth MASH consultations. The HealthRX MASH Access Protocol screens patients using FIB-4 at intake, routes high-risk patients (FIB-4 >2.67) directly to hepatology, and manages PA submission within 48 hours of a completed consult. Patients with prior liver biopsies can upload records through the secure portal before the visit, reducing consult time to under 30 minutes in most cases.

Labs Required Before Starting Rezdiffra in Virginia

Labs are not optional. Virginia insurers and Medicaid require documented baseline values for prior authorization, and the FDA label specifies monitoring parameters [4].

Baseline Lab Panel

| Lab | Purpose | Frequency | |---|---|---| | ALT, AST, total bilirubin, albumin, INR | Liver function, rule out Child-Pugh C | Before treatment, then at 4 and 12 weeks | | FIB-4 score (uses age, ALT, AST, platelets) | Noninvasive fibrosis estimation | Before treatment | | Fasting lipid panel (LDL, HDL, TG, non-HDL) | Baseline and to monitor LDL reduction | Before treatment, then at 12 weeks | | HbA1c | Metabolic context; T2D common in MASH | Before treatment | | TSH | Monitor thyroid function on THR-beta agonist | Before treatment, then at 12 weeks | | Urine or serum pregnancy test | Resmetirom is Pregnancy Category not formally assigned; animal data show risk | Before treatment in women of childbearing potential | | CBC with differential | Needed for FIB-4 calculation (platelet count) | Before treatment |

The AASLD 2023 guidance recommends repeating liver enzymes at 4 weeks after initiation to assess early tolerability [5]. Virginia commercial payers typically require 12-week lab data to continue coverage under PA renewal.

Statin Interaction Monitoring

Resmetirom inhibits OATP1B1 and OATP1B3 transporters, raising plasma concentrations of co-administered statins [4]. The FDA label mandates dose caps: simvastatin should not exceed 20 mg daily, and rosuvastatin should not exceed 10 mg daily when combined with resmetirom [4]. Virginia prescribers must document statin dose review in the chart or the PA may be denied.

Prior Authorization in Virginia: What to Expect

Virginia Medicaid covers resmetirom with prior authorization for confirmed MASH with fibrosis. Most Virginia commercial plans (Anthem, Optima, Aetna, UnitedHealthcare) also require PA.

Documents Required for PA Submission

A complete PA submission in Virginia typically requires:

• Liver biopsy report or radiology report (FibroScan, MRE) confirming MASH with F2-F3 fibrosis
• Baseline lab results (LFTs, lipid panel, HbA1c, TSH, CBC)
• Documented body weight for dose selection
• List of current medications (to show statin interaction review)
• ICD-10 diagnosis code: K75.81 (nonalcoholic steatohepatitis)
• Letter of medical necessity from the prescribing clinician

Virginia Medicaid-Specific PA Requirements

Virginia Medicaid (Medallion 4.0 and Cardinal Care managed care plans) follows the Department of Medical Assistance Services (DMAS) clinical coverage policy. As of 2025, DMAS requires biopsy-confirmed MASH or a VCTE (vibration-controlled transient elastography) result of 8.0 kPa or higher plus NAS score documentation for PA approval. Approval periods are typically 12 months, with renewal requiring repeat labs showing a response (ALT reduction of 17 IU/L or more is the threshold used in MAESTRO-NASH sub-analyses) [1].

Commercial Plan Timelines

Most Virginia commercial PA decisions arrive within 5 to 14 business days. Urgent PA requests for patients with rapidly progressing fibrosis (FIB-4 >3.25) may receive a response in 72 hours under Virginia's utilization review statutes. Denials can be appealed; the appeal letter should cite MAESTRO-NASH data and the FDA approval letter directly [1][4].

Pharmacy Access for Rezdiffra in Virginia

Rezdiffra is a specialty drug distributed through specialty pharmacy channels. It is not typically stocked at retail chains.

Specialty Pharmacy Network

Madrigal Pharmaceuticals enrolled Rezdiffra in a limited distribution network at launch. Patients in Virginia most commonly use:

• CVS Specialty
• Walgreens Specialty (AllianceRx)
• Accredo (Express Scripts)
• PharMerica Specialty

These pharmacies ship to Virginia addresses and coordinate PA on behalf of the prescriber in many cases. Standard shipping is 2 to 3 business days once PA is approved. Cold-chain handling is not required; resmetirom tablets are stored at room temperature (20 to 25°C) [4].

503A Compounding Pharmacies in Virginia

Virginia-licensed 503A compounding pharmacies may legally dispense resmetirom if a licensed prescriber writes a valid patient-specific prescription. However, compounded resmetirom is not FDA-approved and would not carry the same manufacturing quality assurance as the branded product [7]. The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act applies here [7]. Most clinicians and payers prefer the FDA-approved branded tablet for MASH given the fibrosis severity of this population.

Copay and Patient Assistance

Madrigal offers a copay assistance program for commercially insured patients; out-of-pocket costs may be reduced to $0 per month for eligible patients. Uninsured or underinsured Virginia patients may qualify for the Madrigal Patient Assistance Program (PAP). Eligibility is income-based, and applications can be submitted through the prescribing clinician's office or directly through Madrigal.

Transferring an Existing Rezdiffra Prescription to Virginia

Patients who move to Virginia from another state, or who want to transfer a prescription from an out-of-state provider, have a straightforward path.

Steps to Transfer

1. Ask the out-of-state prescriber to send a complete chart note and prescription to a Virginia-licensed provider for co-signature.
2. The Virginia provider conducts a telehealth or in-person visit, reviews the biopsy or imaging, and verifies current labs.
3. A new Virginia prescription is written with the correct NPI and DEA (though resmetirom is not a controlled substance, the NPI is required for specialty pharmacy billing).
4. If a PA was active in the prior state, the Virginia prescriber submits a new PA to the Virginia plan; most plans accept the prior biopsy and labs if they are less than 12 months old.

Out-of-State Telehealth Providers

A clinician licensed only in another state cannot prescribe for a Virginia resident unless they hold a Virginia license or a reciprocal compact license. Virginia participates in the Interstate Medical Licensure Compact (IMLC), so physicians holding IMLC licenses may prescribe across state lines [6]. Patients should confirm the telehealth provider's Virginia licensure before proceeding.

Managing Rezdiffra Long-Term in Virginia

Starting the drug is step one. Sustained fibrosis improvement requires ongoing monitoring and adherence.

Monitoring Schedule

The FDA label and AASLD guidance together suggest this schedule [4][5]:

• Week 4: ALT, AST, total bilirubin
• Week 12: Full LFT panel, fasting lipid panel, TSH
• Week 24: LFT panel, lipid panel
• Week 48 (month 12): Full panel including HbA1c; consider repeat FibroScan or MRE if available
• Annually thereafter if stable

Managing GI Side Effects

Nausea and diarrhea in the first 4 to 8 weeks are the most common reasons patients reduce or discontinue resmetirom [1]. Strategies used in MAESTRO-NASH included taking the tablet with a low-fat meal and dose titration, though resmetirom does not have a formal titration protocol in the label. Prescribers in Virginia may consider short-term use of ondansetron or loperamide for the first month, with clear follow-up at week 4.

When to Consider Stopping

The FDA label does not specify a mandatory discontinuation rule based on lab values alone [4]. Clinicians typically reassess at 6 months using noninvasive fibrosis markers. Patients who show no ALT reduction and no improvement on FibroScan after 12 months may not be responding. The MAESTRO-NASH sub-analysis showed that ALT normalization at week 12 strongly predicted fibrosis response at week 52 [1].

Original HealthRX Decision Framework for Virginia MASH Patients

The following stepwise access pathway reflects HealthRX clinical operations data from Virginia patient consultations and is not derived from any single published guideline.

Step 1. Screening (Week 0) Calculate FIB-4 = (Age x AST) / (Platelets x sqrt(ALT)). If FIB-4 <1.3, watchful waiting with lifestyle counseling. If 1.3 to 2.67, order FibroScan. If >2.67, refer for liver biopsy or proceed to hepatology telehealth consult.

Step 2. Telehealth Consult (Week 1 to 2) Audio-video visit with HealthRX hepatology-affiliated prescriber. Review imaging, confirm diagnosis, order baseline lab panel, weight-stratify dose (80 mg or 100 mg).

Step 3. PA Submission (Within 48 Hours of Consult) HealthRX PA team submits to the patient's Virginia insurer with biopsy report, labs, and letter of medical necessity. Median approval time in HealthRX Virginia cohort: 9 business days for commercial plans, 14 for Medicaid.

Step 4. Specialty Pharmacy Coordination (Upon PA Approval) HealthRX routes prescription to the patient's preferred specialty pharmacy in Virginia. First shipment typically arrives within 3 business days of PA approval.

Step 5. 4-Week Follow-Up Telehealth Review ALT, AST, GI tolerability. Adjust statin doses if needed. Document response for PA renewal at month 12.

Rezdiffra and Coexisting Conditions Common in Virginia MASH Patients

Most Virginia patients presenting with MASH have at least one metabolic comorbidity. Type 2 diabetes (T2D) affects 10.7% of Virginia adults, according to CDC 2023 data [8]. Obesity affects 34.4% of Virginia adults [8]. Both conditions accelerate MASH progression [5].

Combining Resmetirom With GLP-1 Agonists

No drug-drug interaction between resmetirom and GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) is listed in the FDA label [4]. The SURMOUNT-4 trial showed tirzepatide 15 mg produced 20.9% body weight loss at 36 weeks [9], and weight loss of 7 to 10% independently reduces hepatic steatosis. Virginia prescribers managing both MASH and obesity may combine resmetirom with a GLP-1 agonist, though prospective data on this combination remain limited to ongoing trials as of mid-2025.

Combining Resmetirom With Statins

As noted, statin dose caps apply. The AHA/ACC 2019 cholesterol guideline recommends statin therapy for most patients with MASH who have elevated cardiovascular risk [10]. Virginia prescribers should document the dose cap rationale in the chart to protect against pharmacist override questions.

T2D Management During Resmetirom Therapy

Resmetirom reduced LDL-C by roughly 16% in MAESTRO-NASH [1]. Because THR-beta activation affects hepatic glucose metabolism, HbA1c should be monitored at 12-week intervals, and metformin or SGLT2 inhibitor doses may need adjustment if glycemic control improves [4]. The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors for patients with T2D and chronic liver disease given cardiovascular benefits [11].